Literature DB >> 19017451

Cost-effectiveness of a new interferon-based blood assay, QuantiFERON-TB Gold, in screening tuberculosis contacts.

F Marra1, C A Marra, M Sadatsafavi, O Morán-Mendoza, V Cook, R K Elwood, M Morshed, R C Brunham, J M Fitzgerald.   

Abstract

BACKGROUND: Recent approval of interferon-gamma release assays that are more specific for Mycobacterium tuberculosis has given new options for the diagnosis of latent tuberculosis infection (LTBI).
OBJECTIVE: To assess the cost-effectiveness of Quanti-FERON-TB Gold (QFT-G) vs. the tuberculin skin test (TST) in diagnosing LTBI in contacts of active TB cases using a decision analytic Markov model.
METHODS: Three screening strategies--TST alone, QFT-G alone and sequential screening of TST then QFT-G--were evaluated. The model was further stratified according to ethnicity and bacille Calmette-Guérin (BCG) vaccination status. Data sources included published studies and empirical data. Results were reported in terms of the incremental net monetary benefit (INMB) of each strategy compared with the baseline strategy of TST-based screening in all contacts.
RESULTS: The most economically attractive strategy was to administer QFT-G in BCG-vaccinated contacts, and to reserve TST for all others (INMB CA$3.70/contact). The least cost-effective strategy was QFT-G for all contacts, which resulted in an INMB of CA$-11.50 per contact. Assuming a higher prevalence of recent infection, faster conversion of QFT-G, a higher rate of TB reactivation, reduction in utility or greater adherence to preventive treatment resulted in QFT-G becoming cost-effective in more subgroups.
CONCLUSIONS: Selected use of QFT-G appears to be cost-effective if used in a targeted fashion.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017451

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  19 in total

1.  Utilization of the QuantiFERON-TB Gold test in a two-step process with the tuberculin skin test to evaluate health care workers for latent tuberculosis.

Authors:  Baha Abdalhamid; Steven H Hinrichs; Jodi L Garrett; Jean M O'Neill; Kristine M Hansen-Cain; Amy A Armbrust; Peter C Iwen
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

Review 2.  Recent advances in testing for latent TB.

Authors:  Neil W Schluger; Joseph Burzynski
Journal:  Chest       Date:  2010-12       Impact factor: 9.410

3.  Is it time to replace the tuberculin skin test with a blood test?

Authors:  Philip A LoBue; Kenneth G Castro
Journal:  JAMA       Date:  2012-07-18       Impact factor: 56.272

4.  Priorities for screening and treatment of latent tuberculosis infection in the United States.

Authors:  Benjamin P Linas; Angela Y Wong; Kenneth A Freedberg; C Robert Horsburgh
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

5.  Screening immigrants for latent tuberculosis: do we have the resources?

Authors:  Jonathon Campbell; Fawziah Marra; Victoria Cook; James Johnston
Journal:  CMAJ       Date:  2014-01-27       Impact factor: 8.262

6.  Recommendations on Interferon Gamma Release Assaysfor the Diagnosis of Latent Tuberculosis Infection-2010 Update: An Advisory Committee Statement (ACS) Canadian Tuberculosis Committee (CTC)*.

Authors:  Dennis Kunimoto; Drs Michael Gardam; Ian Kitai; Dick Menzies; Muhammad Morshed; Madhukar Pai; Heather Ward; Duncan Webster; Wendy Wobeser
Journal:  Can Commun Dis Rep       Date:  2010-06-01

7.  Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States.

Authors:  Anna K Person; Neela D Goswami; Deborah J Bissette; Debra S Turner; Ann V Baker; L Beth Gadkowski; Susanna Naggie; Kirby Erlandson; Luke Chen; Tahaniyat Lalani; Gary M Cox; Jason E Stout
Journal:  AIDS Patient Care STDS       Date:  2010-09       Impact factor: 5.078

8.  Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.

Authors:  Anil Pooran; Helen Booth; Robert F Miller; Geoff Scott; Motasim Badri; Jim F Huggett; Graham Rook; Alimuddin Zumla; Keertan Dheda
Journal:  BMC Pulm Med       Date:  2010-02-22       Impact factor: 3.317

9.  Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease.

Authors:  Mike van der Have; Bas Oldenburg; Herma H Fidder; Tim D G Belderbos; Peter D Siersema; Martijn G H van Oijen
Journal:  Dig Dis Sci       Date:  2013-08-15       Impact factor: 3.199

10.  Evaluation of the tuberculin skin test and the interferon-gamma release assay for TB screening in French healthcare workers.

Authors:  Dominique Tripodi; Benedicte Brunet-Courtois; Virginie Nael; Marie Audrain; Edmond Chailleux; Patrick Germaud; Frederique Naudin; Jean-Yves Muller; Martine Bourrut-Lacouture; Marie-Henriette Durand-Perdriel; Claire Gordeeff; Guyonne Guillaumin; Marietherese Houdebine; Francois Raffi; David Boutoille; Charlotte Biron; Gilles Potel; Claude Roedlich; Christian Geraut; Anja Schablon; Albert Nienhaus
Journal:  J Occup Med Toxicol       Date:  2009-11-30       Impact factor: 2.646

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.